Waters ACQUITY UPLC H-Class System
Designed to Replace HPLC Systems and Accelerate UPLC Adoption among HPLC Users
Waters® ACQUITY UPLC® H-Class System:
Designed to Replace HPLC Systems and Accelerate UPLC Adoption among HPLC Users
The new Waters® ACQUITY UPLC® H-Class System makes the productivity and chromatography performance benefits of UPLC accessible to HPLC users.
This combination of performance, simplicity and flexibility is designed to help more laboratories realize the scientific and business benefits of sub-2-μm (micron) particle column technology by making it more accessible to a broader range of industries, applications and operators.
Featuring a new quaternary solvent manager with flow-through needle design, the system allows those running HPLC methods access to UPLC-quality resolution, sensitivity, and speed. The system’s low-dispersion design results in high-efficiency separations while new method transfer kits along with three particle substrates in 11 chemistries – ranging in particle size from 5 micron to 1.7 micron – accommodates a broad range of applications and methods development approaches.
Waters ACQUITY UPLC H-Class System is built on UPLC technology which has proven to increase laboratory productivity, enable faster time-to-market, and increase profitability by reducing manufacturing costs, all while improving the quality of the information produced. Waters is now demonstrating the ACQUITY UPLC® H-Class System in all of its worldwide application laboratories and shipping units to customers. For more information: Click here.
Brian J. Murphy
Waters Corporation
+1 508-482-2614
brian_j_murphy@waters.com
Detailed Glycosylation Analysis of Therapeutic Enzymes Utilizing Comprehensive 2D-LC–MS
January 3rd 2025In this article, the use of comprehensive two-dimensional liquid chromatography (LC×LC) coupled to mass spectrometry (MS) for characterizing glycosylation of therapeutic enzymes is presented.
Advancing Gene Therapy: Enzyme Selection for Effective RNA Oligonucleotide Mapping
New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), continue to make progress in both primate and first-in-human trials. As this progress builds, the industry remains accountable for characterizing these molecules to meet the requirements of regulatory authorities.
